Artemis Medicare

Who are in the management team of Artemis Medicare?

As of March 2023, the management team of Artemis Medicare includes Deepa Gopalan Wadhwa, Sunil Tandon, Shalini Kanwar Chand, Onkar S Kanwar (Chairman), Neeraj Kanwar, S Narayan, Nirmal Kumar Ganguly, Sanjaya Baru, Sanjib Sen, Devlina Chakravarty (Managing Director), and Poonam Makkar (Company Secretary). The team comprises a mix of independent directors and company executives.

As of March 2023, the management team of Artemis Medicare includes the following individuals:<BR><BR>1. Deepa Gopalan Wadhwa - Independent Director<BR>2. Sunil Tandon - Independent Director<BR>3. Shalini Kanwar Chand - Director<BR>4. Onkar S Kanwar - Chairman & Director<BR>5. Neeraj Kanwar - Director<BR>6. S Narayan - Independent Director<BR>7. Nirmal Kumar Ganguly - Director<BR>8. Sanjaya Baru - Independent Director<BR>9. Sanjib Sen - Independent Director<BR>10. Devlina Chakravarty - Managing Director<BR>11. Poonam Makkar - Company Secretary & Compliance Officer<BR><BR>This diverse team includes a mix of independent directors and company executives, contributing to the governance and management of Artemis Medicare.

Has Artemis Medicare declared dividend?

Artemis Medicare Services Ltd has declared a 45% dividend, amounting to 0.45 per share, with an ex-date of July 5, 2024. Despite a recent 6-month price return of -21.46%, the company has shown strong total returns over longer periods, particularly a 1358.88% total return over the past 5 years.

Artemis Medicare Services Ltd has declared a 45% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.46%, with a dividend return of 0%, resulting in a total return of -21.46%.<BR><BR>Over the past year, the price return was 53.3%, with a dividend return of 0.25%, leading to a total return of 53.55%.<BR><BR>In the 2-year period, the price return was 205.4%, with a dividend return of 0.88%, culminating in a total return of 206.28%.<BR><BR>For the 3-year period, the price return was 472.81%, with a dividend return of 2.26%, resulting in a total return of 475.07%.<BR><BR>In the last 4 years, the price return was 860.16%, with a dividend return of 2.87%, leading to a total return of 863.03%.<BR><BR>Finally, over the past 5 years, the price return was 1353.8%, with a dividend return of 5.08%, resulting in a total return of 1358.88%.<BR><BR>Overall, Artemis Medicare has shown significant total returns over the years, particularly in the longer term, despite a recent negative price return in the last 6 months. The declared dividend indicates a commitment to returning value to shareholders, although the yield remains relatively low.

Who are the peers of the Artemis Medicare?

Peers of Artemis Medicare include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Dr Agarwal's Eye, Shalby, GPT Healthcare, and KMC Speciality. In terms of performance, Fortis Health leads with a 1-year return of 60.01%, while Artemis Medicare has a return of 55.32%.

Peers: The peers of Artemis Medicare are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Dr Agarwal's Eye, Shalby, GPT Healthcare, and KMC Speciality.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, and GPT Healthcare, while Average management risk is found at Fortis Health., Dr Agarwal's Eye, Shalby, and KMC Speciality, and the rest. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Fortis Health., Narayana Hrudaya, and the rest, while Average growth is seen at Global Health, Dr Agarwal's Eye, and Shalby, with Below Average growth at Artemis Medicare and KMC Speciality. Capital Structure is Excellent at Max Healthcare and GPT Healthcare, Good at Fortis Health. and Shalby, Average at Artemis Medicare, and Average at the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 60.01%, while the lowest is Shalby at -28.92%. Artemis Medicare's 1-year return of 55.32% is significantly higher than Shalby's but lower than Fortis Health.'s. Additionally, Global Health, Shalby, GPT Healthcare, and KMC Speciality have negative six-month returns.

What does Artemis Medicare do?

Artemis Medicare Services Ltd operates multi-specialty hospitals and was established in 2004, with its first hospital opening in 2007. As of March 2025, it reported net sales of ₹2,399 Cr and a net profit of ₹230 Cr, with a market cap of ₹3,487 Cr.

Overview: <BR>Artemis Medicare Services Ltd is engaged in managing and operating multi-specialty hospitals within the hospital industry and falls under the small-cap market category.<BR><BR>History: <BR>The company was incorporated on May 18, 2004, and commenced commercial operations by establishing Artemis Hospital (formerly Artemis Health Institute) in Gurugram on July 16, 2007. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2,399 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 230 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 3,487 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 42.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.18% <BR>Debt-Equity: -0.13 <BR>Return on Equity: 9.86% <BR>Price-to-Book: 4.21 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Artemis Medicare?

The top shareholder of Artemis Medicare is Constructive Finance Private Limited, holding 67.17%. Other significant shareholders include the Governor of Kerala at 4.91%, mutual funds at 1.96%, foreign institutional investors at 0.31%, and individual investors with a collective stake of 12.86%.

The top shareholders of Artemis Medicare primarily include the promoters, with Constructive Finance Private Limited holding the highest stake at 67.17%. The promoters collectively have a significant portion of the shares, with 44.53% of their holdings pledged. In terms of public shareholders, the Governor of Kerala is the largest, holding 4.91%. Additionally, mutual funds hold 1.96% across four schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.31% through 24 different entities. Individual investors collectively own 12.86% of the company.

How big is Artemis Medicare?

As of 24th July, Artemis Medicare Services Ltd has a market capitalization of 3,327.00 Cr, with recent Net Sales of 936.91 Cr and a Net Profit of 82.63 Cr. Shareholder's Funds are 837.68 Cr, and Total Assets are valued at 1,357.41 Cr.

As of 24th July, Artemis Medicare Services Ltd has a market capitalization of 3,327.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 936.91 Cr and a Net Profit of 82.63 Cr.<BR><BR>For the latest annual period, the Shareholder's Funds amounted to 837.68 Cr, while the Total Assets were valued at 1,357.41 Cr.

Is Artemis Medicare overvalued or undervalued?

As of October 16, 2025, Artemis Medicare is considered fairly valued with a PE ratio of 38.36 and a favorable comparison to peers like Apollo Hospitals and Max Healthcare, despite a recent underperformance against the Sensex, but it shows strong long-term growth potential.

As of 16 October 2025, Artemis Medicare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 38.36, an EV to EBITDA of 20.65, and a PEG ratio of 0.72, which suggests a reasonable growth expectation relative to its price.<BR><BR>In comparison to its peers, Artemis Medicare's valuation appears more favorable. For instance, Apollo Hospitals, which is also rated attractive, has a significantly higher PE ratio of 71.71, while Max Healthcare is categorized as very expensive with a PE of 94.88. Despite recent underperformance compared to the Sensex, with a year-to-date return of -23.26% versus the Sensex's 6.82%, Artemis Medicare's strong growth in the long term, as evidenced by a 273.78% return over three years, reinforces its attractiveness in the market.

How has been the historical performance of Artemis Medicare?

Artemis Medicare has shown consistent growth, with net sales increasing from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, and profit after tax rising from INR 31.40 crore to INR 82.18 crore during the same period. The company has improved its operating profit margin and cash flow, indicating strong operational efficiency.

Answer:<BR>The historical performance of Artemis Medicare shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Artemis Medicare's net sales have increased significantly from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025. Operating profit (PBDIT) also saw substantial growth, climbing from INR 71.35 crore in March 2022 to INR 184.78 crore in March 2025, with an operating profit margin that improved from 12.16% to 16.2% over the same period. Profit before tax increased from INR 37.18 crore in March 2022 to INR 107.67 crore in March 2025, and profit after tax rose from INR 31.40 crore to INR 82.18 crore. The company's total assets grew from INR 709.66 crore in March 2022 to INR 1,357.41 crore in March 2025, while total liabilities increased from INR 709.66 crore to INR 1,357.41 crore as well. Cash flow from operating activities improved from INR 59 crore in March 2022 to INR 145 crore in March 2025, indicating enhanced operational efficiency. Overall, Artemis Medicare has demonstrated robust growth in sales, profits, and asset base, positioning itself favorably in the market.

Is Artemis Medicare technically bullish or bearish?

As of December 2, 2025, the trend has shifted to bullish with moderate strength, supported by positive indicators like the MACD, RSI, and moving averages, although caution is advised due to some bearish signals on the monthly timeframe.

As of 2 December 2025, the technical trend has changed from mildly bearish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include a bullish MACD on the weekly chart, a bullish RSI on the monthly chart, and bullish signals from moving averages on the daily timeframe. The KST and OBV are also bullish on the weekly timeframe, while the Bollinger Bands show a mildly bullish trend. However, the monthly MACD and KST remain mildly bearish, indicating some caution. Overall, the bullish trend is supported by recent price action, despite a recent decline from the previous close.

When is the next results date for Artemis Medicare Services Ltd?

The next results date for Artemis Medicare Services Ltd is February 2, 2026.

The next results date for Artemis Medicare Services Ltd is scheduled for February 2, 2026.

Are Artemis Medicare Services Ltd latest results good or bad?

Artemis Medicare Services Ltd's latest results show strong operational growth with a net profit increase of 40.84% quarter-on-quarter; however, the stock has declined 23.52% over the past year, raising concerns about sustainability and capital efficiency. Investors should remain cautious due to these mixed signals and governance issues.

Artemis Medicare Services Ltd's latest results present a mixed picture. On one hand, the company reported strong operational performance in the recent quarter, with a net profit of ₹29.97 crores, reflecting a substantial 40.84% increase quarter-on-quarter and a 34.64% rise year-on-year. Revenue also grew by 7.74% quarter-on-quarter and 13.79% year-on-year, indicating solid growth momentum.<BR><BR>However, despite these positive results, the company's stock has struggled significantly over the past year, declining 23.52%. This underperformance is notable when compared to the Sensex, which increased by 5.37%, and the broader hospital sector, which grew by 12.12%. The divergence between strong quarterly results and weak stock performance raises concerns among investors about the sustainability of the recent gains and the company's modest return ratios, with a return on equity (ROE) of only 9.51%.<BR><BR>Additionally, there are concerns regarding capital efficiency, as the company operates with a relatively low return on capital employed (ROCE) of 10.87%. The recent decline in promoter shareholding from 66.53% to 58.39% also raises questions about confidence in the company's future prospects.<BR><BR>In summary, while Artemis Medicare's latest results show impressive growth and margin expansion, the overall sentiment is tempered by concerns over stock performance, capital efficiency, and governance issues. Investors may want to adopt a cautious approach, monitoring future developments closely.

Should I buy, sell or hold Artemis Medicare Services Ltd?

Why is Artemis Medicare Services Ltd falling/rising?

As of 08-May, Artemis Medicare Services Ltd's stock price is slightly declining at 265.35, following five days of gains. Despite this short-term drop, the stock has strong long-term performance indicators and fundamentals, suggesting potential for recovery.

As of 08-May, Artemis Medicare Services Ltd is experiencing a slight decline in its stock price, currently at 265.35, reflecting a change of -0.75 (-0.28%). This decrease comes after a period of five consecutive days of gains, indicating a trend reversal. Despite this recent drop, the stock has shown strong performance over various time frames, with a 1-week increase of 8.51% and a 1-month increase of 15.27%, significantly outperforming the Sensex during these periods.<BR><BR>The stock's performance today has underperformed its sector by 2.12%, which may contribute to the current decline. However, it is noteworthy that Artemis Medicare is trading above its moving averages across multiple time frames, suggesting overall positive momentum in the longer term. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 81.97% compared to the 5-day average, indicating growing interest in the stock despite the current price drop.<BR><BR>Financially, the company maintains a strong position with a low Debt to EBITDA ratio of 1.69 times, healthy operating profit growth, and positive results over the last eight consecutive quarters. These factors contribute to a solid long-term outlook, even as the stock faces short-term fluctuations. Overall, while the stock is currently falling, its historical performance and strong fundamentals suggest potential for recovery and growth in the future.

Which are the latest news on Artemis Medicare?